Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

You may be eligible if

• Diagnosis of 1 of the following hematologic malignancies:
• * Hodgkin's lymphoma
• * Non-Hodgkin's lymphoma (NHL)
• * Multiple myeloma
• Patients in the phase II portion of the study are enrolled in 1 of the following strata according to diagnosis\*
• * Stratum 1: Indolent B-cell NHL (non-Hodgkin's lymphoma), follicle center B-cell NHL (grade 1, 2, or 3), marginal zone lymphoma, Waldenstrom's macroglobulinemia, or small lymphocytic lymphoma (without blood lymphocytosis at any point in the disease process)
• * Must have progressive lymphadenopathy, worsening cytopenias, or progressive symptoms attributed to lymphoma
• * Must require therapy, as determined by progressive anemia, thrombocytopenia, symptoms (e.g., fever, night sweats, weight loss, or fatigue), or progressive lymphadenopathy that causes discomfort
• * Received ≥ 2 prior therapies, including rituximab
• * Stratum 1a: Hairy cell leukemia
• * Must require therapy, as determined by progressive cytopenias or symptoms (fever, night sweats, weight loss, or fatigue)
• * Must have received ≥ 2 therapies
• * Stratum 2: Mantle cell lymphoma, as determined by the presence of cyclin D1 staining OR t(11;14)
• * Stratum 3: Intermediate grade B-cell NHL, including diffuse large B-cell NHL and T-cell rich B-cell NHL
• * Diffuse large B-cell NHL arising from an indolent NHL (i.e., transformed lymphoma) allowed
• * Ineligible for potentially curative autologous stem cell transplantation
• * Stratum 4: T-cell and natural killer-cell NHL, including anaplastic large cell lymphoma and peripheral T-cell NHL
• * Primary cutaneous lymphoma or Sezary syndrome allowed provided criteria for measurable disease are met
• * Received ≥ 1 prior systemic therapy
• * Stratum 5: Hodgkin's lymphoma
• * Any of the following subtypes are allowed:
• * Nodular sclerosing
• * Mixed cellularity
• * Lymphocyte predominant
• * Lymphocyte depleted
• * Ineligible for potentially curative autologous stem cell transplantation
• * Stratum 6: Progressive stage I or stage II or IIIA multiple myeloma meeting ≥ 1 major and 1 minor criterion OR ≥ 3 minor criteria as follows:
• * Major criteria
• * Plasmacytoma on tissue biopsy
• * Bone marrow plasmacytosis ≥ 30% of marrow cellularity
• * Monoclonal paraprotein ≥ 3,500 mg/dL (IgG), or ≥ 2,000 mg/dL (IgA), OR monoclonal protein (Bence-Jones protein) ≥ 1,000 mg by 24-hour urine collection
• * Minor criteria
• * Bone marrow plasmacytosis 10-29% of marrow cellularity
• * Monoclonal paraprotein \< 3,500 mg/dL (IgG) or \< 2,000 mg/dL (IgA)
• * Lytic bone lesions by x-ray or CT scan
• * Decrease in normal IgM (\< 50 mg/dL), IgA (\< 100 mg/dL), or IgG (\< 600 mg/dL)
• Relapsed or refractory disease
• Measurable disease, defined by 1 of the following:
• * At least 1 node \> 2 cm by CT scan
• * Measurable disease in a lymphoid structure (i.e., spleen) by CT scan
• * Bone marrow involvement (\> 20% of marrow cellularity)
• * Patients with multiple myeloma must have detectable serum or urinary paraprotein
• Must have received ≥ 1 prior therapy
• * Steroids alone are not considered prior therapy for patients with NHL or Hodgkin's lymphoma
• * High-dose dexamethasone is considered 1 prior therapy for patients with multiple myeloma
• No standard effective therapy exists
• No HIV-associated lymphoma
• No nonsecretory multiple myeloma
• Performance status - ECOG (Eastern Cooperative Oncology Group) 0-2
• No concurrent hormonal therapy except steroids for new adrenal failure or hormones administered for non-disease-related conditions (e.g., insulin for diabetes)
• Hemoglobin ≥ 9.0 g/dL\*
• Absolute neutrophil count ≥ 1,500/mm\^3\*
• Platelet count ≥ 50,000/mm\^3\*
• AST (aspartate aminotransferase) ≤ 3 times upper limit of normal (ULN)
• Bilirubin ≤ 2 times ULN
• No major renal dysfunction that would preclude study compliance or participation
• Phase I:
• * Creatinine ≤ 1.5 mg/dL
• * Creatinine clearance ≥ 70 mL/min
• Phase II:
• * Creatinine ≤ 2.0 mg/dL
• * Creatinine clearance ≥ 50 mL/min
• No cardiac or vascular dysfunction that would preclude central venous access, vigorous hydration, or hemodialysis
• No other major cardiac dysfunction that would preclude study compliance or participation
• No major pulmonary dysfunction that would preclude study compliance or participation
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No chronic gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) that would preclude study compliance or participation
• No other major organ system (including neurological or psychiatric) dysfunction that would preclude study compliance or participation
• Prior radiotherapy, including radioimmunotherapy, allowed
• No concurrent radiotherapy
• Prior idiotype vaccination or stem cell transplantation allowed
• More than 6 weeks since prior mitomycin or nitrosoureas
• No other concurrent chemotherapy
• More than 4 weeks since other prior therapy
• Prior systemic steroids allowed